DrugPatentWatch Database Preview
Drugs in Development Information for Galactose
What is the development status for investigational drug Galactose?
Galactose is an investigational drug.
There have been 22 clinical trials for Galactose.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Syndrome, Mucopolysaccharidosis IV, and Mucopolysaccharidoses. The leading clinical trial sponsors are BioMarin Pharmaceutical, University of Aarhus, and Aarhus University Hospital.
There are two US patents protecting this investigational drug and twenty-four international patents.
Summary for Galactose
| US Patents | 2,586 |
| International Patents | 24,270 |
| US Patent Applications | 3,537 |
| WIPO Patent Applications | 3,014 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 3 (2012-09-01) |
| Vendors | 30 |
Recent Clinical Trials for Galactose
| Title | Sponsor | Phase |
|---|---|---|
| Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 Gangliosidosis | Axovant Sciences, Inc. | Phase 1/Phase 2 |
| Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 Gangliosidosis | National Human Genome Research Institute (NHGRI) | Phase 1/Phase 2 |
| Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia | Applied Therapeutics, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Galactose
Top disease conditions for Galactose
Top clinical trial sponsors for Galactose
US Patents for Galactose
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Galactose | Start Trial | GAL-1 variants having immuno-modulating properties and methods of using the same | Consejo Nacional de Investigaciones Cientificas Y Tecnicas (Buenos Aires, AR) Fundacion Sales (Buenos Aires, AR) INIS Biotech LLC (Milford, DE) | Start Trial |
| Galactose | Start Trial | Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer | OGD2 PHARMA (Nantes, FR) UNIVERSITE DE NANTES (Nantes, FR) | Start Trial |
| Galactose | Start Trial | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) | Start Trial |
| Galactose | Start Trial | Methods and systems for growing plants using silicate-based substrates, cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives, and formulations, processes and systems for the same | Innovation Hammer, LLC (Powell, OH) | Start Trial |
| Galactose | Start Trial | Multiuse, enzymatic detergent and methods of stabilizing a use solution | Ecolab USA Inc. (Saint Paul, MN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Galactose
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Galactose | Argentina | 104674 | 2035-04-21 | Start Trial |
| Galactose | Australia | 2016252737 | 2035-04-21 | Start Trial |
| Galactose | Brazil | 112017022715 | 2035-04-21 | Start Trial |
| Galactose | Canada | 2999843 | 2035-04-21 | Start Trial |
| Galactose | European Patent Office | 3285797 | 2035-04-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
